The daily upper limits for vitamin D include intakes from all sources – food, beverages, and supplements – and are listed below in micrograms (mcg) and International Units (IU). For adults 19 years and older, the UL is 100 mcg (4,000 IU). The ULs do not apply to people who are taking vitamin D under the care of a physician. Taking more than the UL for a long time increases the chance of side effects.

The Tolerable Upper Intake Level (UL) for vitamin D ranges from 25 to 100 mcg (1,000–4,000 IU), depending on age. The UL is defined as the maximum daily intake unlikely to cause adverse health effects. The FNB noted that serum concentrations greater than 125 nmol/L (50 ng/mL) can be associated with adverse effects, and that even vitamin D intakes lower than the ULs might have adverse health effects over time. "While acknowledging that signs and symptoms of toxicity are unlikely at daily intakes below 250 mcg (10,000 IU), the FNB noted that even vitamin D intakes lower than the ULs might have adverse health effects over time" and recommended avoiding serum 25(OH)D levels above about 125–150 nmol/L.

The news release on the 2024 Clinical Practice Guideline states: "Healthy adults under the age of 75 are unlikely to benefit from taking more than the daily intake of vitamin D recommended by the Institutes of Medicine (IOM) and do not require testing for vitamin D levels." It lists as a key recommendation: "We suggest against vitamin D supplements at doses beyond the reference dietary intakes recommended by the IOM in healthy adults under 75 years old." For adults 50 years and older who do need vitamin D, the guideline also notes: "we suggest daily, lower-dose vitamin D instead of non-daily, higher-dose vitamin D."

For its 2011 report, the Institute of Medicine (IOM) has set the UL for vitamin D at 4000 international units (IU) daily for those aged 9 years or older, based on the assumption that hypercalcemia is unlikely to occur at daily vitamin D doses below 10,000 IU. This meta-analysis of 22 RCTs concluded: "Supplemental vitamin D doses of 3,200–4,000 IU/d appear to increase the risk of hypercalcemia and some other adverse events in a small proportion of individuals, indicating that this dose is not completely safe." Across studies, "the frequency of hypercalcemia in the control and vitamin D group was 0.21% and 0.63%, respectively, resulting in a vitamin D-induced frequency of hypercalcemia of 0.42% or 4 cases per 1,000 individuals." Risks of falls (RR 1.25) and hospitalization (RR 1.16) were also significantly increased.

The 2011 Institute of Medicine report established a Tolerable Upper Intake Level (UL) for vitamin D of 4,000 IU/day (100 mcg) for adults and children 9 years and older, intended as the highest level of daily intake that is likely to pose no risk of adverse health effects to almost all individuals. The committee noted that case reports of toxicity generally involved intakes of 10,000 IU/day or higher, but also cited emerging evidence of a U‑shaped relationship between serum 25(OH)D and health outcomes, with potential adverse effects at high concentrations. Thus, while acknowledging that toxicity is rare at usual supplemental doses, the report cautioned that there is limited data on long‑term intakes near the UL and that susceptible individuals may experience adverse effects at lower doses.

This 2024 review, written by members of the Endocrine Society guideline group, explains that in contrast to earlier 2011 guidance, "in adults, aged 19-74 yr, the panel recommended against routine vitamin D supplementation [that exceeds the dietary reference intakes (DRI) for age]" and that adults should consume the DRI of 600 IU for those 50–70 years and 800 IU for those over 70 years through food and/or supplements. It notes for pregnant and lactating people: "Dosage range 600-5000 IU daily" and for adults with high‑risk prediabetes: "Daily dosage 842-7543 IU." The paper comments that large randomized controlled trials show that supplementation with the doses of vitamin D3 summarized in the review "is safe and not generally associated with adverse outcomes such as hypercalcemia and kidney stones."

In the full 2024 guideline PDF, the panel writes: "The panel suggests against empiric vitamin D supplementation above the current DRI to lower the risk of disease in healthy adults younger than 75 years." It specifies that adults ages 19–74 years who are not pregnant or prediabetic should follow the IOM recommendations, i.e., 600 IU daily for 19–69 years and 800 IU for 70–74 years. For pregnancy, the guideline notes that empiric supplementation is suggested because of potential benefits and comments that in the clinical trials evaluated in pregnancy "the vitamin D doses used ranged from 600 to 5000 IU/day," with an estimated average intake around 2500 IU/day.

Vitamin D toxicity is rare. There are around 4,500 cases per year in the United States. The dose of vitamin D you need to take to produce toxic signs and symptoms varies greatly. It can occur with as little as 2,000 international units per day (IU/d) in susceptible people. Symptoms of vitamin D toxicity are mainly due to hypercalcemia and can include vomiting, increased thirst and frequent urination.

The 2024 guideline panel suggests against routine vitamin D supplementation in healthy adults younger than 75 years for the prevention of disease because benefits are uncertain. For adults who choose to take vitamin D supplements, the panel recommends adhering to established upper intake limits (generally 4,000 IU per day for adults) to minimize the risk of adverse effects such as hypercalcemia and nephrolithiasis. The guideline notes that very high chronic intakes of vitamin D can lead to toxicity, although such cases are rare.

Summarising the 2023 EFSA opinion, the German Federal Institute for Risk Assessment notes that EFSA used hypercalcemia and hypercalciuria as indicators of vitamin D toxicity and that a LOAEL was identified at daily administration of 250 µg vitamin D with calcium for 1–3 years, which led to persistent hypercalciuria. The BfR concludes that weekly intakes corresponding to 20,000 IU/week "have the potential to increase serum 25‑OH‑D levels to above 100 nmol/l" in individuals with high status, but that at such levels "the risk of adverse effects, such as hypercalcaemia, appears to be relatively low."

The Endocrine Society’s patient summary for the 2024 guideline says that for people at low risk: "For people at low-risk of low vitamin D, this guideline suggests the daily doses of vitamin D defined by the IOM. This includes those between 19 and 74 years of age who are not pregnant or pre-diabetic (600 IU daily for those aged between 19 and 69 years, and 800 IU for those aged between 70 and 74 years)." Regarding pregnancy, it notes: "The doses used in the studies evaluated ranged from 600 to 5000 IU/day (15 to 125 μg), with an estimated average of 2500 IU (63 μg) per day." It states these pregnancy trials suggested possible benefits on preeclampsia, intra-uterine mortality, preterm birth, low birth weight and neonatal mortality.

Vitamin D treatment appears to be safe at doses of up to 10,000 IU day−1, delivering 25OHD concentrations below levels associated with toxicity. Indeed, others have shown that an average daily intake of 15,000 IU day−1 and plasma 25OHD concentrations up to 300 nmol l−1 are not associated with deranged calcium or phosphate metabolism or toxicity. The features of vitamin D toxicity are mediated through hypercalcaemia, and symptoms range from mild, such as thirst and polyuria, to severe, including seizures, coma and death.

In this clinical study of 282 vitamin D–deficient, statin‑intolerant patients, vitamin D3 at 50,000–100,000 IU/week (about 7,000–14,000 IU/day) for 12 months was reported as "safe and effective," with investigators noting that serum vitamin D "rarely exceeded 100 ng/mL, never reached toxic levels, and there were no significant change in serum calcium or eGFR." The authors further comment that previous data showed that daily doses of vitamin D3 up to 10,000 IU were safe in healthy males and that studies using 4,000 IU/day for a year reported no adverse effects attributable to vitamin D.

A community-based study of 3,667 subjects receiving vitamin D3 reported that "dosing with 10,000 IU/day was safe, with no reported serum 25(OH)D level >200 ng/mL." The paper cites that serum 25(OH)D levels are usually markedly elevated (>150 ng/mL) in individuals with vitamin D intoxication and that daily doses of vitamin D3 up to 10,000 IU were safe in healthy male volunteers.

Higher doses of vitamin D may be dangerous. Vitamin D doesn't dissolve in water, so it can't be excreted through urine; instead, excess vitamin D builds up in the body tissues and bloodstream. In rare cases, taking a supplement that contains too much vitamin D can be toxic: It can lead to hypercalcemia, a condition in which too much calcium builds up in the blood, potentially forming deposits in the arteries or soft tissues. A study of older people already at risk for falls found an increased fall risk among those taking higher doses of vitamin D (50 mcg to 100 mcg, or 2,000 IU to 4,000 IU), compared with lower doses (250 IU to 1,000 IU). The article advises: "Unless your medical team recommends it, avoid taking more than 100 mcg (4,000 IU) per day, which is considered the safe upper limit."

Randomized trials of vitamin D supplementation in generally healthy adults have not shown consistent benefits for non-skeletal outcomes. The tolerable upper intake level for vitamin D is 4,000 IU per day for adults, and intakes above this may increase the risk of adverse events such as hypercalcemia and nephrolithiasis in susceptible individuals. While vitamin D toxicity is rare, case reports demonstrate that toxicity can occur at a wide range of doses, particularly when high doses are taken chronically or when dosing errors occur.

The Endocrine Society guideline recommends that adults who are vitamin D deficient be treated with higher doses initially, then maintained on 1,500–2,000 IU/day, and notes that short‑term treatment with up to 10,000 IU/day may be used to correct deficiency. However, it distinguishes these therapeutic regimens from routine supplementation and emphasizes that sustained high doses should be supervised because of the risk of hypercalcemia and other adverse outcomes in susceptible individuals.

This systematic review underpinning the 2024 Endocrine Society guideline summarizes evidence on benefits and harms of vitamin D. It reports that in healthy adults aged 19 to 74 years there was "no significant effect on select outcomes" of empiric vitamin D supplementation, at varying doses, with variable certainty. It also notes safety findings, including that administration of "high-dose intermittent vitamin D may increase falls, compared to lower-dose daily dosing," while daily lower-dose regimens were not linked to major harms. The review is the basis for the panel’s caution against routine high-dose supplementation in generally healthy adults.

This review describes vitamin D toxicity as usually resulting from "prolonged use (months) of vitamin D megadoses, i.e. in excess of 10,000 IU/day," leading to marked hypercalcemia and very high serum 25(OH)D levels. However, it notes that there is considerable inter‑individual variability and that cases of toxicity have occurred at lower intakes when other risk factors (such as high calcium intake, renal disease, or certain granulomatous disorders) are present. The authors emphasize that although doses of 4,000 IU/day are often considered safe for the general population, a small proportion of individuals may develop hypercalcemia or other complications at or below this intake, particularly with long‑term use.

The NIH notes that symptoms of vitamin D toxicity are most likely to appear when a person’s daily intake is at least 10,000 IU (250 mcg). However, experts have cautioned that much smaller amounts could be associated with health risks. The NIH indicates that even amounts less than the Tolerable Upper Intake Level (UL) of 4,000 IU (100 mcg) could have negative health effects over time. Generally, it’s not recommended to exceed the Tolerable Upper Intake Level (UL), which is 4,000 IU (100 mcg) per day.

This registered randomized controlled trial in healthy adults tests the effect of "supplementation of oral vitamin D3 at a dose of 5000 IU/day" for 8 weeks on cardiometabolic risk markers. The study hypothesis notes an expected increase in plasma 25(OH)D with 5,000 IU/day; safety outcomes such as serum calcium and adverse events are included among secondary measures, indicating that the dose is being formally evaluated for both efficacy and safety.

At recommended doses (600–1,000 IU/day), side effects are uncommon. At higher doses (4,000+ IU/day), potential effects include nausea, vomiting, loss of appetite, constipation, muscle weakness, headache, confusion, irritability, metallic taste, and fatigue. Vitamin D toxicity results from excessive supplementation and causes hypercalcemia with serum 25(OH)D typically above 150 ng/mL. Symptoms can progress to dehydration, kidney stones, kidney failure, cardiac arrhythmias, and calcification of soft tissues.

It is important to note that toxicity is uncommon and generally only occurs in individuals who take high, long-term doses of supplements without monitoring their blood levels. However, excessive vitamin D can lead to dangerously high calcium levels in the blood, causing uncomfortable and potentially harmful symptoms. Signs of vitamin D toxicity or high calcium levels in the blood include digestive issues such as vomiting, nausea, and stomach pain; fatigue, dizziness, and confusion; increased thirst; and frequent urination. The article advises that generally, 4,000 IU or less per day is considered safe, as long as your blood levels are monitored.

The Institute of Medicine (now the National Academy of Medicine) set the tolerable upper intake level (UL) for vitamin D at 4,000 IU/day for adults based on clinical trial data and case reports. The UL was established at a level that is unlikely to pose a risk of adverse health effects for almost all individuals in the general population, but it is not a guaranteed ‘no side effects’ threshold. Some susceptible individuals may experience adverse effects at intakes below the UL, whereas many people can tolerate higher intakes without symptoms.